- Home
- BP Efficacy
- Severe Hypertension
- LIFE BP Lowering
- QD Efficacy
- COZAAR vs Valsartan
- COZAAR vs Valsartan & Irbesartan
- Outcomes
- LIFE Outcomes
- RENAAL Outcomes
- Resources
- Video Presentations
- Related Links
- Patient Profiles
- Coverage & Availability
- Merck Prescription Discount Program
- Patient Assistance Programs
- Managed Care Formulary Coverage
- Contact Us
- Request More Information
- Prescribing Information
- Patient Information
USE IN PREGNANCY: When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, COZAAR and HYZAAR should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.
Home | BP Efficacy | Outcomes | Resources | Patient Profiles | Coverage & Availability | Contact Us | Request More Information | Prescribing Information | Patient Information
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
COZAAR and HYZAAR are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Delaware, USA.
20851323(3)-07/08-COZ
